Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance

UnknownOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

October 1, 2020

Study Completion Date

October 1, 2020

Conditions
Kidney Transplant Rejection
Interventions
DEVICE

AlloSure

Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.

Trial Locations (8)

21201

University of Maryland, Baltimore

23298

Virginia Commonwealth University, Richmond

33606

Tampa General Hosptial, Tampa

55455

University of Minnesota Medical Center, Minneapolis

63110

Washington University, St Louis

77030

Memorial Hermann Hosptial, Houston

80045

University of Colorado Hospital, Aurora

84107

Intermountain Medical Center, Murray

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CareDx

INDUSTRY

NCT04566055 - Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance | Biotech Hunter | Biotech Hunter